suvmax values (Wolters Kluwer Health)
90
Structured Review
Wolters Kluwer Health
suvmax values
Suvmax Values, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/suvmax/suvmax/10__1097_slash_rlu__0000000000004903-101-9-3
Average 90 stars, based on 1 article reviews
Suvmax Values, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/suvmax/suvmax/10__1097_slash_rlu__0000000000004903-101-9-3
Average 90 stars, based on 1 article reviews
suvmax values - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Bone Uptake in Prostate Cancer Patients Article Snippet: Purpose: Gallium-labeled prostate-specific membrane antigen-11 (PSMA) PET/CT is the new reference to identify relapse during biochemical recurrence of prostate cancer (PCa).. However, this method lacks specificity for bone foci.. This study aimed to report the prevalence of PCa bone metastases and to assess the diagnostic performances of PSMA reporting and data systems (RADS), clinical, biological, and imaging features for identification. Article Title: The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors Article Snippet: Purpose:The aim of this study was to identify and evaluate the role of GaDOTA–somatostatin analog (SSA) PET/CT in guiding treatment for patients with neuroendocrine tumors (NETs) based on published literature, with specific focus on the ability of PET/CT to impact clinical management and predict peptide receptor radionuclide therapy (PRRT) response.. Patients and Methods: A systematic literature search of articles up to December 2021 was performed using PubMed and Scopus.. Eligible studies included ≥10 patients with confirmed or suspected NETs who had undergone pretreatment staging Ga-DOTA-SSA PET/CT. Article Title: Relationship between 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters and clinicopathology in endometrial cancer Article Snippet: Results The median age of these 101 patients was 55 years (range, 35–85 years), and 95 patients (94.1%) presented with abnormal vaginal bleeding, 26 patients (25.7%) with elevated serum cancer antigen 125 (CA-125) and 46 patients (45.5%) with increased human epididymis protein 4 (HE4).. Sixty-nine cases were at International Federation of Gynecology and Obstetrics (FIGO) stage I, eight at stage II, 20 at stage III, and four at stage IV.. FDG uptake was avid in all cases, and the median SUVmax, MTV-P, TLG-P, MTV-C, and TLG-C were 12.9 (range, 2.8–34.2), 8.1 (range, 0.9–547.8), 52.2 (range, 2.5–4420.6), 8.2 (range, 0.9–790.3), and 58.4 (range, 2.5–6972.2), respectively. Positron Emission Tomography:Article Title: Imaging for illuminating actionable pathways in breast cancer Article Snippet: Purpose of review Nuclear medicine has the potential to explore and illuminate several pathways in breast cancer (BC) offering different radiopharmaceuticals for positron emission tomography (PET) designed to target specific tumor characteristics.. The aim of this critical review is to give an overview about emerging opportunities in PET imaging, underlining the future potential contribution in the management of BC patients. Quantitation Assay:Article Title: Role of 18F-FDG PET/CT in the Assessment of Response to Antitubercular Chemotherapy and Identification of Treatment Endpoint in Patients With Tuberculosis of the Joints Article Snippet: Aims: The aim of this study was to explore the utility of F-FDG PET/CT in the assessment of response to antitubercular treatment (ATT) and identification of treatment endpoint.. Patients and Methods: Forty patients (mean age, 35.3 years; 27 men) with clinically, radiologically, and histopathologically proven joint tuberculosis prospectively underwent clinical, biochemical, and PET/CT evaluation at baseline and after ~6, 12, and 18 months of ATT.. Two patients were lost to follow-up, and 1 defaulted treatment. Activity Assay:Article Title: Role of 18F-FDG PET/CT in the Assessment of Response to Antitubercular Chemotherapy and Identification of Treatment Endpoint in Patients With Tuberculosis of the Joints Article Snippet: Aims: The aim of this study was to explore the utility of F-FDG PET/CT in the assessment of response to antitubercular treatment (ATT) and identification of treatment endpoint.. Patients and Methods: Forty patients (mean age, 35.3 years; 27 men) with clinically, radiologically, and histopathologically proven joint tuberculosis prospectively underwent clinical, biochemical, and PET/CT evaluation at baseline and after ~6, 12, and 18 months of ATT.. Two patients were lost to follow-up, and 1 defaulted treatment. Injection:Article Title: Role of 18F-FDG PET/CT in the Assessment of Response to Antitubercular Chemotherapy and Identification of Treatment Endpoint in Patients With Tuberculosis of the Joints Article Snippet: Aims: The aim of this study was to explore the utility of F-FDG PET/CT in the assessment of response to antitubercular treatment (ATT) and identification of treatment endpoint.. Patients and Methods: Forty patients (mean age, 35.3 years; 27 men) with clinically, radiologically, and histopathologically proven joint tuberculosis prospectively underwent clinical, biochemical, and PET/CT evaluation at baseline and after ~6, 12, and 18 months of ATT.. Two patients were lost to follow-up, and 1 defaulted treatment. |